Published May 26, 2021
Futurity reported on research led by biomedical engineering Jonathan Lovell that found an experimental nanoparticle-based flu vaccine consisting of disease-fighting proteins was proven effective in preclinical studies. The technology could boost the effectiveness and accelerate the production of seasonal flu vaccines.
“Typically, flu vaccines contain either deactivated microbes that cause influenza, or they are based on weakened forms of the disease,” said Lovell, an associate professor and SUNY Empire Innovation Professor in the Department of Biomedical Engineering. “The vaccine we’re developing is a recombinant protein nanoparticle vaccine that stimulates a strong immune response.”
The paper, "A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge," was published in the Proceedings of the National Academy of Sciences.
Read the Futurity story here. Global News and Technology.org also reported on the study.
